<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="2" ids="35475">Non-steroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) and hormone therapy (HT) independently decrease the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, their role in altering survival after a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> diagnosis is not well established </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We examined the association between the use of these common medications before diagnosis and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> survival among women in western Washington State diagnosed with incident <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> from 1997 to 2002 </plain></SENT>
<SENT sid="3" pm="."><plain>Cases were ascertained using the Surveillance, Epidemiology and End Results <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registry; mortality follow-up was completed through linkages to the National <z:hpo ids='HP_0011420'>Death</z:hpo> Index </plain></SENT>
<SENT sid="4" pm="."><plain>Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We observed no overall association between <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> survival and pre-diagnostic <z:chebi fb="1" ids="35475">NSAID</z:chebi> use </plain></SENT>
<SENT sid="6" pm="."><plain>However, when stratified by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> sub-site, <z:chebi fb="1" ids="35475">NSAID</z:chebi> use was associated with a reduced risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> mortality for women diagnosed with proximal (HR=0.55; 95% CI: 0.32-0.92), but not distal or rectal (HR=1.32; 95% CI: 0.83-2.10) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The usage of HT was not associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> survival overall or by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> sub-site </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Usage of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> before diagnosis may be associated with improved <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> survival among women diagnosed with proximal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The usage of HT does not appear to have a function in altering <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> mortality </plain></SENT>
</text></document>